校正软组织厚度的更新骨小梁评分(TBSTT)在FREEDOM研究事后分析中显示地舒单抗显著改善骨微结构
FREEDOM事后分析纳入279例完成3年DXA亚研究的绝经后骨质疏松女性(安慰剂129例、地舒单抗150例),比较BMI校正TBS与软组织厚度校正TBS(TBSTT)。地舒单抗组TBSTT从基线至36个月呈进行性升高,12至36个月较基线和安慰剂均有显著差异(p<0.0001),且TBSTT对治疗的响应似乎优于TBSBMI并与BMD无关。
要点
- 地舒单抗组TBSTT从基线至1、12、24、36个月分别变化0.4%、2.3%、2.6%、3.3%。
- 12至36个月TBSTT及TBSBMI较基线及安慰剂均显著改善(p<0.0001)。
- TBSTT在12、24、36个月的变化幅度数值上大于TBSBMI,且与BMD相关性差。
核心结论
- 在绝经后骨质疏松女性中,地舒单抗治疗3年显著改善了TBSTT评估的骨微结构。
- TBSTT似乎比TBSBMI对地舒单抗治疗更敏感,且独立于骨密度。
研究设计与样本
- FREEDOM研究事后分析,纳入完成3年DXA亚研究并进入开放标签延伸研究的279例绝经后骨质疏松女性(安慰剂129例、地舒单抗150例)。
- 受试者腰椎或全髋骨密度T值<-2.5且≥-4.0,随机接受安慰剂或地舒单抗60 mg皮下注射每6个月一次。
- 在基线及第1、12、24、36个月腰椎DXA扫描上评估TBSBMI和TBSTT。
主要发现
- 地舒单抗组BMD从基线至第1、12、24、36个月分别变化1.2%、5.6%、8.1%、10.5%。
- 地舒单抗组TBSTT从基线至第1、12、24、36个月分别变化0.4%、2.3%、2.6%、3.3%。
- 地舒单抗组TBSTT在第12、24、36个月较基线和安慰剂的变化幅度数值上大于TBSBMI。
- 从第12个月至36个月,两种TBS较基线及安慰剂的变化均显著(p<0.0001)。
- BMD与TBSTT在基线及治疗期间变化均相关性差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: TBS algorithm has been updated to account for regional soft tissue noise. In postmenopausal women with osteoporosis, denosumab improved tissue thickness-adjusted TBS vs placebo independently of bone mineral density over 3 years, with the magnitude of changes from baseline or placebo numerically greater than body mass index-adjusted TBS. INTRODUCTION: To evaluate the effect of denosumab on bone microarchitecture assessed by trabecular bone score (TBS) in the FREEDOM study using the updated algorithm that accounts for regional soft tissue thickness (TBSTT) in dual-energy X-ray absorptiometry (DXA) images and to compare percent changes from baseline and placebo with classical body mass index (BMI)-adjusted TBS (TBSBMI). METHODS: Postmenopausal women with lumbar spine or total hip bone mineral density (BMD) T score < - 2.5 and ≥ - 4.0 received placebo or denosumab 60 mg subcutaneously every 6 months. TBSBMI and TBSTT were assessed on lumbar spine DXA scans at baseline and months 1, 12, 24, and 36 in a subset of 279 women (129 placebo, 150 denosumab) who completed the 3-year FREEDOM DXA substudy and rolled over to open-label extension study. RESULTS: Baseline characteristics were similar between groups. TBSTT in the denosumab group showed numerically greater changes from both baseline and placebo than TBSBMI at months 12, 24, and 36. Denosumab led to progressive increases in BMD (1.2, 5.6, 8.1, and 10.5%) and TBSTT (0.4, 2.3, 2.6, and 3.3%) from baseline to months 1, 12, 24, and 36, respectively. Both TBS changes were significant vs baseline and placebo from months 12 to 36 (p < 0.0001). As expected, BMD and TBSTT were poorly correlated both at baseline and for changes during treatment. CONCLUSION: In postmenopausal women with osteoporosis, denosumab significantly improved bone microstructure assessed by TBSTT over 3 years. TBSTT seemed more responsive to denosumab treatment than TBSBMI and was independent of BMD.
引用
- Hans D, Shevroja E, McDermott M, et al. Updated trabecular bone score accounting for the soft tissue thickness (TBSTT) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis. Osteoporos Int. 2022. PMID: 36115888. doi:10.1007/s00198-022-06549-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。